Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Altimmune Inc.
Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro
New Phase II data shows combination of semaglutide plus a novel amylin analog outperforms semaglutide alone, and could surpass Lilly’s Mounjaro in helping weight loss in diabetes patients.
Altimmune Hit By Nasal COVID-19 Vaccine Failure, But Has A Plan B
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
Your Annual COVID-19 Vaccine Booster Could Be A Pill Or A Spray
A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.
Finance Watch: One Week Of IPOs Total $818.2m
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
- Other Names / Subsidiaries
- Immune Targeting Systems (ITS) Ltd.
- ImmuneFocus Corporation
- PharmAthene Inc.
- Spitfire Pharma, Inc.
- Vaxin Pharmaceuticals
- Vaxin Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.